CHINA GOVERNMENTS SIGNALS OPPOSITION TO MEDICINE PRICE FIXING WITH FINES
February 1st, 2016
MAINLAND China’s powerful National Development & Reform Commission (NRDC) has fined five Chinese pharmaceutical companies a total of Chinese Yuan Renminbi CNY4 million (USD612,000) over claims they illegally collided to fix prices allopurinol. It is widely used across China for treating gout and hyperuricemia. Three manufacturers were fined: Chongqing Qingyang, Jiangsu Shimaotianjie and Shanghai Xinyi, who together control the China-based supply of allopurinol. The NRDC concluded they had struck price fixing deals with distributors Chongqing Datong and ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.